Welcome and Opening Remarks

Richard L. Schilsky

Chairman WIN Consortium, Villejuif, France

Josep Tabernero

Vice-Chairman WIN Consortium, Villejuif, France
Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

Opening Keynote Lecture

Re-imagining the (r)evolution in the Precision Oncology paradigm: the future is now

Vivek Subbiah

The University of Texas, MD Anderson Cancer Center, Houston, USA

Keynote Lecture

Expression profiling to discover molecularly and clinically distinct cancer subtypes and to predict response to therapy

Louis M. Staudt

National Cancer Institute (NCI), Bethesda, USA

Keynote Lecture

Functional genomics to identify cancer vulnerabilities

René Bernards

Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

Accelerating precision oncology using multi-omics and AI

Olivier Elemento

Weill Cornell Medicine, New York, USA

Modeling gene regulatory processes to understand cancer and identify therapies

John Quackenbush

Harvard T.H. Chan School of Public Health, Boston, USA

SIMS and Digital Display Precision Predictor algorithms

Vladimir Lazar

WIN Consortium, Villejuif, France

Harnessing a synthetic lethality analysis for patient stratification: key role of transcriptomics

Eytan Ruppin

National Institute of Health (NIH), Bethesda, USA

Panel Discussion

Keynote opening Lecture

Bringing single cell analyses to the clinics

Andrea Califano

Columbia University Medical Center, New York, USA

Keynote lecture

Identifying new uses for approved, targeted drugs: Updates from the ASCO TAPUR study

Richard L. Schilsky

WIN Consortium, Villejuif, France

Genomic and transcriptomic signatures and innovation in CRC
cancers

Josep Tabernero

Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

Phase 3 trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: comprehensive tumor genomic and transcriptomic analyses

Jean-François Martini

Pfizer, Inc., San Diego, USA

Patient stratification/selection for treatments with Tepotinib in
the era of personalized medicine

Ilhan Celik

Merck KGaA, Darmstadt, Germany

Satellite Symposium